2025年中国CSU药物行业发展现状、竞争格局及趋势预测

Core Viewpoint - The CSU (Chronic Spontaneous Urticaria) drug market is experiencing significant growth, driven by technological innovations, policy support, and an increasing number of patients, with projections indicating a market size increase from 124 billion to 417 billion by 2030, reflecting a compound annual growth rate (CAGR) of 16.2% from 2024 to 2030 [1][13]. Industry Overview - CSU is a common allergic disease characterized by recurrent hives and itching lasting more than six weeks, with a growing market for drugs aimed at treating this condition [6][7]. - The CSU drug industry consists of a collaborative supply chain, including research and development, manufacturing, and market distribution, which is continuously improving due to technological advancements and supportive policies [8][9]. Market Size and Growth - The CSU drug market size is projected to grow from 124 billion in 2019 to 169 billion in 2024, with expectations to reach 417 billion by 2030 [13][14]. - The global prevalence of CSU is also increasing, with the number of patients rising from 65.5 million in 2018 to an estimated 69.7 million by 2024, indicating a stable demand for treatment [11][12]. Competitive Landscape - Historically, foreign companies like Novartis dominated the CSU drug market with their product Omalizumab, but they now face challenges due to patent expirations and increasing competition from domestic firms [15][17]. - Domestic companies such as Tianchen Biotech and Jimin Kexin are emerging with innovative treatments, including next-generation anti-IgE antibodies, which may disrupt the current market dynamics [15][17]. Research and Analysis Methodology - The research team employs a combination of desktop research, quantitative surveys, and qualitative analysis, utilizing various models such as SCP, SWOT, PEST, and regression analysis to comprehensively assess the CSU drug industry [2][22]. - A detailed report titled "2025-2031 China CSU Drug Industry Market Research and Development Trend Forecast" has been compiled to provide insights for enterprises, research institutions, and investment organizations [22].